Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Kisspeptin-10
Kisspeptin is central to regulating hormone secretion linked to reproduction.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range100 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range500 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Kisspeptin-10
What published studies and recent community write-ups report about amounts, timing and course length. 9 clinical, 2 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical9 rows | |||||
| Intravenous bolus dose-response and infusions in healthy menHealthy men (6 for the bolus series, 4 per infusion study) | 0.01-3.0 mcg/kg single boluses (maximal effect at 1 mcg/kg); infusions of 4 mcg/kg/h for 22.5 hours or 1.5 mcg/kg/h for 9 hours | Boluses given in ascending order on separate days a week apart; one continuous infusion per study | Intravenous | Single study days; the longest exposure was a 34-hour supervised stayNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed Central)2011 |
| LH rose from 4.1 to 12.4 IU/L within 30 minutes of a 1 mcg/kg bolus, and 3 mcg/kg produced a smaller rise than 1 mcg/kg. The 22.5-hour infusion lifted mean LH from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L in four men, while the lower 9-hour rate increased LH pulse frequency from 0.7 to 1.0 pulses per hour; these are physiological probe studies in a handful of volunteers, not a dosing trial. | |||||
| Men versus women, including the only subcutaneous bolus dataHealthy men and healthy women, 4-5 per dose group | Intravenous bolus 0.3-10 nmol/kg; in women also subcutaneous bolus up to 32 nmol/kg and intravenous infusion up to 720 pmol/kg/min | Single doses on separate study visits | Intravenous bolus, subcutaneous bolus or intravenous infusion | Single visitsNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)2011 |
| Men showed LH rises at 0.3 nmol/kg and FSH rises at 1.0 nmol/kg, but women in the follicular phase had no gonadotropin response to any route at the highest doses tested, and only women in the preovulatory phase responded, to a 10 nmol/kg intravenous bolus. This remains the only published subcutaneous kisspeptin-10 bolus data in humans, and it found no effect in the women who received it. | |||||
| Women under different sex steroid conditions24 women: 10 in the early follicular phase, 6 postmenopausal, 8 using hormonal contraception | 0.3 mcg/kg | Single bolus | Intravenous | 60 minutes of sampling after the doseNot applicable | Human Reproduction (PubMed)2012 |
| LH rose in the follicular, postmenopausal and progestogen-implant groups but not in women on the combined pill, and postmenopausal women had the largest LH and FSH responses. The authors flag that only acute responses were measured and that continuous exposure in women had not been studied. | |||||
| Men with type 2 diabetes and low testosterone5 men with type 2 diabetes and low testosterone (mean age 34, BMI 41) and 7 healthy men | 0.3 mcg/kg bolus; 4 mcg/kg/h infusion for 11 hours | One bolus day, then one infusion day 5 days later | Intravenous | Two study daysNot applicable | Clinical Endocrinology (PubMed)2013 |
| The bolus raised LH from 4.7 to 10.7 IU/L in the diabetic men, a response comparable to the healthy controls, and the 11-hour infusion in four of them raised LH to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L with more frequent LH pulses. The authors call it a proof-of-concept study; no follow-up trial has tested kisspeptin-10 as a testosterone treatment. | |||||
| Head-to-head infusions of kisspeptin-10, kisspeptin-54 and GnRHHealthy men, 5 per dose group | 0.1, 0.3 or 1.0 nmol/kg/h, with double that rate for the first 30 minutes | One 3-hour infusion per visit, visits at least a week apart in random order | Intravenous infusion | 3 hoursNot applicable | Human Reproduction (PubMed)2015 |
| At equal molar doses kisspeptin-10 and kisspeptin-54 produced similar LH and FSH output, while GnRH produced about three times the LH of kisspeptin-10. The sample was small, and the authors note that kisspeptin is the less potent but possibly more physiological stimulus. | |||||
| Hyperprolactinemic amenorrhea, exploratory infusion2 women aged 32 and 36 with cabergoline-resistant microprolactinomas and chronic amenorrhea | 1.5 mcg/kg/h | One 12-hour infusion, after a vehicle day with the same 10-minute sampling | Intravenous infusion | 12 hoursNot applicable | Journal of the Endocrine Society (PubMed)2017 |
| Kisspeptin-10 restored LH pulses and raised LH, FSH, estradiol, testosterone and inhibin B in both women, suggesting the GnRH deficit of high prolactin sits upstream at the kisspeptin level. Two participants make this hypothesis-generating only. | |||||
| Kisspeptin stimulation test in children with delayed puberty16 children (3 girls, 13 boys) with delayed or stalled puberty, followed to adulthood | 0.313 mcg/kg, with a 75 ng/kg GnRH bolus during the same admission | Single bolus | Intravenous | One overnight admission with sampling every 10 minutes, then clinic review every 6 monthsNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed Central)2020 |
| All 8 children whose LH rose by 0.8 mIU/mL or more after kisspeptin later went through puberty on their own, while all 8 whose rise was 0.4 mIU/mL or less reached 18 without physical signs of puberty. This is a diagnostic use of a single dose; the test outperformed GnRH stimulation, inhibin B and genetic testing in this cohort. | |||||
| Pubertal-stage bolus study in boys (registered trial)25 healthy boys, 5 at each Tanner stage, plus 5 adult men, in Islamabad | Fixed doses of 9.5, 11.5, 12.67, 15.11 and 20.5 mcg for Tanner stages I to V (the registry lists them as body-weight based); 1 mcg/kg in adults | Single bolus | Intravenous | Sampling from 30 minutes before to 120 minutes after the doseNot applicable | ClinicalTrials.gov2017 |
| The registry records a non-randomized, unmasked basic-science study that began in 2014 and enrolled 30 participants. The 2018 publication reported no significant LH or testosterone response in Tanner stages I to III, a testosterone rise at stage IV and both LH and testosterone rises at stage V, which the authors read as receptor sensitivity developing late in puberty. | |||||
| Chronic subcutaneous infusion for 5 and 12 days (longest human exposure)15 healthy men across three sub-studies (7, 4 and 7), with 12 vehicle controls | Acute: 1.25-10 nmol/kg/h for 8 hours; continuous: 180 nmol/h for 5 days; intermittent: 150 nmol/h for 8 hours a day for 12 days (about 195 mcg per hour at a molar mass of 1302.4 g/mol), followed by a 1 nmol/kg test bolus | 8 hours on, 16 hours off each day in the 12-day arm | Subcutaneous infusion by pump | 5 days continuous or 12 days intermittentA 16-hour daily pause in the intermittent arm | European Journal of Endocrinology (PubMed)2026 |
| Acute subcutaneous infusions raised LH, FSH and testosterone in a dose-dependent way, but five days of continuous infusion let gonadotropins drift back to vehicle levels even though testosterone stayed up. The 8-hours-on schedule sustained the LH increase through day 12 (mean rise 1.68 IU/L on day 1 and 1.14 IU/L on day 12) and the receptor still answered a bolus afterwards; this randomized, single-blind, placebo-controlled study is the longest kisspeptin-10 exposure published in people and it used pumps, not injections. | |||||
| Preclinical2 rows | |||||
| Original rat study of central and peripheral kisspeptin-10Adult male rats; rat hypothalamic explants and pituitary fragments | 3 nmol into the brain ventricle for the time course; peripheral injections at doses not given in the abstract; 100-1000 nM on pituitary fragments | Single injection | Intracerebroventricular or peripheral injection | Up to 60 minutes of samplingNot applicable | Journal of Neuroendocrinology (PubMed)2004 |
| Central kisspeptin-10 raised LH within 10 minutes and FSH and testosterone by 60 minutes, peripheral injection raised all three, and the peptide released GnRH from hypothalamic tissue but did nothing to pituitary fragments directly. This 2004 Imperial College study fixed the hypothalamus as the site of action. | |||||
| Twelve days of twice-daily injections in prepubertal rats5-week-old prepubertal male rats | 10 pg, 1 ng or 1 mcg per injection | Twice daily | Intraperitoneal | 12 daysNone | Life Sciences (PubMed)2011 |
| After 12 days plasma LH and testosterone were lower at the 1 ng and 1 mcg doses, daily sperm production fell, and the seminiferous tubules showed necrosis, vacuoles and giant cells on microscopy. It is the clearest animal signal that repeated kisspeptin-10 can suppress an immature axis rather than drive it; it was not repeated in adult animals. | |||||
| Community-reported3 rows | |||||
| Vendor-style guide, two or three injections a week | 100 mcg (starter), 200 mcg (standard) or 500 mcg (upper) per injection; alternatively 6-10 mcg/kg | 2-3 times per week, often in the morning or before sleep | Subcutaneous, lower abdomen or thigh, from a 5 mg vial in 2 mL (25 mcg per unit) | 4-12 weeks (4-8 weeks at 500 mcg)A break equal to the length of the cycle before repeating | Community resource2026 |
| This guide lists the same 100-500 mcg two-to-three-times-weekly pattern that appeared on the legacy page for this compound, yet its own fact-check banner states that no peer-reviewed study supports that protocol and that validated human dosing is intravenous and weight-based. It also describes stacks with gonadorelin, enclomiphene and hCG without any trial behind them. | |||||
| Post-cycle 'axis recovery' and libido protocols | 100 mcg per injection to start; 200-500 mcg per injection in the higher-dose variant; 100-200 mcg on demand 30-90 minutes before an event | Twice daily for weeks 1-4, then once daily for weeks 5-8; an advanced variant uses 50-100 mcg every 90-120 minutes while awake | Subcutaneous (5 mg in 2 mL, 25 mcg per unit) | 8-12 weeks, with lab checks at 4 and 8 weeks2-4 weeks off after each 8-12 week block; a 4-weeks-on, 2-off, 4-on variant is also described | Community resource2026 |
| Aimed at men restarting their own hormone output after anabolic steroids, this 2026 guide quotes a plasma half-life of about 4 minutes, puts the LH dose-response plateau at 500-1,000 mcg and tells readers that progress shows in lab trends rather than in how a dose feels. It states there are no human data on months of use and that its cycling rules are convention, and it relies on kisspeptin-54 trial findings for its tachyphylaxis warning. | |||||
| Tiered daily dosing table with bloodwork checkpoints | 100 mcg start; 200-300 mcg standard; 500 mcg upper range (300-500 mcg for post-cycle use) | Once or twice daily | Subcutaneous | 4-8 weeks for testosterone or libido goals; 8-12 weeks for fertility protocols2-4 weeks off (4 weeks after fertility runs), with LH, FSH and testosterone checked during the break | Community resource2026 |
| The guide admits its kisspeptin-10 ranges are extrapolated from kisspeptin-54 clinical data and warns readers not to convert the nmol/kg doses of those trials into flat microgram doses. It argues that kisspeptin should carry less pituitary desensitization risk than GnRH agonists while conceding that long-term data do not exist. | |||||
How a course is commonly described
- Weeks 1-2Community-reported
Community guides describe starting at 100 mcg subcutaneously, either once daily or two to three times a week, to gauge response before increasing. Most say nothing noticeable happens at this stage and that any effect is to be read from blood tests later.
- Weeks 2-8Community-reported
The quoted working range is 200-500 mcg per injection, once or twice daily in the daily protocols or two to three times a week in the vendor-style ones, with LH, FSH and testosterone checked at 4 and 8 weeks. Guides that target post-cycle recovery step down from twice daily to once daily after week 4.
- BreakCommunity-reported
A 2-4 week pause after each block is the common description, or a break as long as the cycle itself in the two-to-three-times-weekly version, with some guides suggesting bloodwork during the pause to see whether the axis holds up without stimulation. None of these intervals comes from a study.
- Clinical comparisonClinical
Human studies gave kisspeptin-10 as single intravenous boluses of 0.3-1 mcg/kg or as infusions of hours; the only multi-day exposure is the 2026 study of pump infusions for 5 and 12 days, in which continuous delivery let gonadotropins fall back while an 8-hours-on, 16-hours-off schedule kept them raised. No study has given repeated bolus injections for weeks.
- Preclinical cautionPreclinical
In prepubertal rats, twice-daily intraperitoneal kisspeptin-10 for 12 days lowered LH and testosterone and damaged the seminiferous tubules at the 1 ng and 1 mcg doses, the opposite of the stimulation seen after single doses. Whether anything similar applies to adult animals or people is unknown.
- No human study has given kisspeptin-10 by repeated bolus injection for weeks. The published record is single intravenous boluses, infusions of 3 to 24 hours, and one 2026 study of subcutaneous pump infusions for 5 and 12 days in which continuous delivery lost its gonadotropin effect within five days.
- Community guides quote a plasma half-life of about 4 minutes and build daily or twice-daily schedules on that figure, but they draw their desensitization warnings from kisspeptin-54 trials; whether flat 100-500 mcg doses produce the pulse-like LH response seen after weight-based intravenous boluses has not been measured.
- Kisspeptin-10 has no marketing approval and is sold as a research chemical. A 2026 legal summary of the FDA compounding committee notes that the Ohio Board of Pharmacy has taken enforcement action against pharmacies compounding kisspeptin, and women in the follicular phase did not respond at all in the one study that tested them, so female protocols copied from male use have no basis. These rows record what sources report, not recommendations.
Sources for this section (16)
- Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men
- The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans
- Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback
- Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism
- Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
- Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea
- Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay
- Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys (NCT03286517)
- Changes in the Responsiveness of the Hypothalamic-Pituitary-Gonadal Axis to Kisspeptin-10 Administration during Pubertal Transition in Boys
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
- Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis
- Intraperitoneal kisspeptin-10 administration induces dose-dependent degenerative changes in maturing rat testes
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Kisspeptin-10 is the ten-residue, C-terminally amidated tail of kisspeptin, the KISS1 gene product that tells hypothalamic GnRH neurons to fire; it is the smallest kisspeptin fragment that keeps full activity at the KISS1R (GPR54) receptor and occurs naturally as a cleavage product of the 54-residue hormone. Since 2011, groups in Edinburgh, London and Boston have given it to healthy men and women, men with type 2 diabetes, women with prolactin-driven amenorrhea and children with delayed puberty, almost always as a single intravenous bolus or an infusion lasting hours, to probe or restart the reproductive axis; a 2026 study was the first to run subcutaneous infusions for 12 days. It has no marketing approval anywhere and is sold as a research chemical in 2, 5 and 10 mg vials, and the flat 100-500 mcg subcutaneous injections described in the peptide community have never been tested in any trial. In the only study to try it, women in the follicular phase of the cycle did not respond to kisspeptin-10 by any route.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Boosting Gonadotropin-Releasing Hormone
Kisspeptin-10's role in stimulating GnRH release
- 2
Increasing Testosterone
Kisspeptin-10's effects on testosterone levels
- 3
Energy Balance
Kisspeptin-10's role in energy regulation
- 4
Cancer Research
Kisspeptin-10's potential role in cancer treatment and metastasis prevention
- 5
Studied Memory Enhancement
Kisspeptin-10's potential role in memory and learning
- 6
Impact on Mood
Kisspeptin-10's effects on mood and behavior
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Boosting Gonadotropin-Releasing Hormone
Kisspeptin-10's role in stimulating GnRH release
- Not graded
Increasing Testosterone
Kisspeptin-10's effects on testosterone levels
Amounts recorded for Kisspeptin-10
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.100 mcg
- 2Dose · upper endpointSign in for schedule, duration and source context.500 mcg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Also listed as
Metastin (45-54), KP-10, Kisspeptin-10 (human), Human metastin 45-54, Kisspeptin-13 (4-13) (human), UNII FS1N52VS3S, CHEMBL376756, NSC 741805
InChIKey
RITKWYDZSSQNJI-INXYWQKQSA-N
IUPAC name
(2S)-N-[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]butanediamide
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.